SK-OV-3/SK-OV-3/SK-OV-3/人卵巢癌细胞

SK-OV-3/SK-OV-3细胞系/SK-OV-3细胞株/SK-OV-3人卵巢癌细胞

Cell line name SK-OV-3

Synonyms SKOV-3; SK-OV3; SK.OV.3; SKOV3; Skov3; SKO3; SKOV3 (S)

Accession CVCL_0532

Resource Identification Initiative To cite this cell line use: SK-OV-3 (RRID:CVCL_0532)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: JFCR39 cancer cell line panel.

Part of: KuDOS 95 cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: NCI-60 cancer cell line panel.

Part of: OCCP ovarian cancer cell line panel.

From: Memorial Sloan Kettering Cancer Center; New York; USA.

Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-528.

Population: Caucasian.

Doubling time: 44 hours (PubMed=7718330); 19 hours (PubMed=2653399); 28 +- 2 hours (PubMed=3804493); 28.8 hours (PubMed=4016745); 75 hours (PubMed=25984343); 48.7 hours (NCI-DTP=SK-OV-3); ~35 hours (PBCF); 33.29 hours (JWGray panel).

Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Exosome proteome analysis.

Omics: Fluorescence phenotype profiling.

Omics: Genome sequenced.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Misspelling: SCOV-3; Note=Occasionally.

Misspelling: SCOV3; Note=Occasionally.

Misspelling: SKVO3; Note=Occasionally.

Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.

PubMed=9041185

Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.

Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.

Cancer Res. 57:850-856(1997)

 

PubMed=9554442; DOI=10.1093/jnci/90.8.597

Sabichi A.L., Hendricks D.T., Bober M.A., Birrer M.J.

Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide.

J. Natl. Cancer Inst. 90:597-605(1998)

 

PubMed=9698466; DOI=10.1006/gyno.1998.5039

Maxwell G.L., Risinger J.I., Tong B., Shaw H., Barrett J.C., Berchuck A., Futreal P.A.

Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.

Gynecol. Oncol. 70:13-16(1998)

 

PubMed=10318951; DOI=10.1073/pnas.96.10.5722; PMCID=PMC21927

Lau K.-M., Mok S.C., Ho S.-M.

Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.

Proc. Natl. Acad. Sci. U.S.A. 96:5722-5727(1999)

 

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

 

PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H

Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.

Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.

Mol. Carcinog. 28:236-246(2000)

 

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

 

PubMed=11565033; DOI=10.1038/35095068

Moberg K.H., Bell D.W., Pronk-Wahrer D.C.R., Haber D.A., Hariharan I.K.

Archipelago regulates cyclin E levels in Drosophila and is mutated in human cancer cell lines.

Nature 413:311-316(2001)

 

PubMed=11789735; DOI=10.1309/4NCM-QJ9W-QM0J-6QJE

Rhodes A., Jasani B., Couturier J., McKinley M.J., Morgan J.M., Dodson A.R., Navabi H., Miller K.D., Balaton A.J.

A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer.

Am. J. Clin. Pathol. 117:81-89(2002)

 

PubMed=11793438; DOI=10.1002/gcc.1221

Rao P.H., Harris C.P., Lu X.-Y., Li X.-N., Mok S.C., Lau C.C.

Multicolor spectral karyotyping of serous ovarian adenocarcinoma.

Genes Chromosomes Cancer 33:123-132(2002)

 

PubMed=12080474; DOI=10.1038/sj.onc.1205542

Manzano R.G., Montuenga L.M., Dayton M., Dent P., Kinoshita I., Vicent S., Gardner G.J., Nguyen P., Choi Y.-H., Trepel J.B., Auersperg N., Birrer M.J.

CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential.

Oncogene 21:4435-4447(2002)

 

PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x; PMCID=PMC5926887

Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M., Takayama M., Sato A., Inazawa J.

Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.

Jpn. J. Cancer Res. 93:1114-1122(2002)

 

PubMed=12960427; DOI=10.1091/mbc.E03-05-0279; PMCID=PMC266758

Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O.G., Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H., Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J., Kristensen G.B., Borresen-Dale A.-L., Hastie T., Tibshirani R., van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O., Sikic B.I.

Gene expression patterns in ovarian carcinomas.

Mol. Biol. Cell 14:4376-4386(2003)

 

PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742

Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.

HLA class I and II genotype of the NCI-60 cell lines.

J. Transl. Med. 3:11.1-11.8(2005)

 

PubMed=16380993; DOI=10.1002/ijc.21671

Huang K.-C., Park D.C., Ng S.-K., Lee J.Y., Ni X.-Y., Ng W.-C., Bandera C.A., Welch W.R., Berkowitz R.S., Mok S.C., Ng S.-W.

Selenium binding protein 1 in ovarian cancer.

Int. J. Cancer 118:2433-2440(2006)